Cargando…

Gastrointestinal disorders as immune-related adverse events

Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy. Their use in different types of advanced cancer has shown good results...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balducci, Daniele, Quatraccioni, Claudia, Benedetti, Antonio, Marzioni, Marco, Maroni, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Open Exploration 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400751/ https://www.ncbi.nlm.nih.gov/pubmed/36046145 http://dx.doi.org/10.37349/etat.2021.00039

Ejemplares similares

Risk Stratification in Primary Biliary Cholangitis
por: Martini, Francesco, et al.
Publicado: (2023)

Cancer-Associated Fibroblasts in Cholangiocarcinoma: Current Knowledge and Possible Implications for Therapy
por: Montori, Michele, et al.
Publicado: (2022)

Aging-Related Molecular Pathways in Chronic Cholestatic Conditions
por: Pinto, Claudio, et al.
Publicado: (2020)

Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases
por: Pinto, Claudio, et al.
Publicado: (2021)

Gut–Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology
por: Maroni, Luca, et al.
Publicado: (2020)

Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies
por: Giordano, Debora Maria, et al.
Publicado: (2018)

The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
por: Mazzetti, Marta, et al.
Publicado: (2021)

Immune-Related Adverse Events of the Gastrointestinal System
por: Nicolaides, Steven, et al.
Publicado: (2023)

Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy
por: Ninfole, Elisabetta, et al.
Publicado: (2021)

Gastrointestinal adverse events of immunotherapy
por: Cappello, Giovanni, et al.
Publicado: (2021)

Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
por: Rajha, Eva, et al.
Publicado: (2019)

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management
por: Shivaji, Uday N., et al.
Publicado: (2019)

Impact of proton pump inhibitors on the onset of gastrointestinal immune‐related adverse events during immunotherapy
por: Lasagna, Angioletta, et al.
Publicado: (2023)

Gastrointestinal Complications after Allogeneic Hematopoietic Stem Cell Transplant: A Multidisciplinary Approach with Early Endoscopic Evaluation
por: Tarantino, Giuseppe, et al.
Publicado: (2021)

Clinical assessment of immune-related adverse events
por: Sosa, Aaron, et al.
Publicado: (2018)

Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival
por: Yamada, Kentaro, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Functional and Structural Features of Cholangiocytes in Health and Disease
por: Maroni, Luca, et al.
Publicado: (2015)

Immune-related adverse events and prognosis in patients with upper gastrointestinal cancer treated with nivolumab
por: Hara, Yoshihiro, et al.
Publicado: (2022)

Biomarkers for gastrointestinal adverse events related to thiopurine therapy
por: Zudeh, Giulia, et al.
Publicado: (2021)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Cardiovascular immune‐related adverse events: Evaluation, diagnosis and management
por: Liu, Yingxian, et al.
Publicado: (2020)

Mechanisms and biomarkers of immune-related adverse events in gastric cancer
por: Ding, Ping’an, et al.
Publicado: (2023)

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events
por: Les, Iñigo, et al.
Publicado: (2023)

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
por: Badran, Yousef R., et al.
Publicado: (2019)

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Yifan, et al.
Publicado: (2023)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy
por: Vani, Vanina, et al.
Publicado: (2020)

Immune-Related Adverse Events: Pneumonitis
por: Zhong, Linda, et al.
Publicado: (2020)

Serological biomarkers predict immune-related adverse events and clinical benefit in patients with advanced gastrointestinal cancers
por: Wang, Yanni, et al.
Publicado: (2022)

Oral Immune-Related Adverse Events – Current Concepts and their Management
por: Asan, Mohamed Faizal, et al.
Publicado: (2021)

The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events
por: Mytareli, Chrysoula, et al.
Publicado: (2023)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management
por: Stucci, Stefania, et al.
Publicado: (2017)

Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
por: Albarrán-Artahona, Víctor, et al.
Publicado: (2022)

Rheumatic Immune-Related Adverse Events—A Consequence of Immune Checkpoint Inhibitor Therapy
por: Bobircă, Anca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8vdfc68c82tj1knt4mpt8bl8f3